awmsg logo



atazanavir (Reyataz®)


Reference No. 30

Publication date:
21/01/2009


Appraisal information

atazanavir (Reyataz®) capsule


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 12/11/2008
AWMSG meeting date: 10/12/2008
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2408
Ministerial ratification: 19/01/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Atazanavir (Reyataz®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-naive patients, in accordance with British HIV Association (BHIVA) guidance. Atazanavir (Reyataz®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download